When Dilaudid is taken orally, it reaches its peak effect in 30 minutes to an hour. The elimination half-life of oral Dilaudidis about 4 hours.
Dilaudid can cause serious or life-threatening breathing problems, especially during the first two days of taking the medication or if your doctor increases the dosage. You should be carefully monitoredwhen you start taking this medication.
You must not drink alcohol while using Dilaudid. Other medications can affect how Dilaudid works in your system. It is very important to discuss all other prescriptions, over-the-counter medications, vitamins, and herbs with your doctor or pharmacist so they can advise you and adjust your prescriptions properly for safety.
Specific medications to be aware of interactions with hydromorphone include MAO inhibitors, blood pressure medicine, diuretics (water pills), medicine for depression, phenothiazine, and anything that makes you sleepy. It also can have interactions with St. John’s wort and tryptophan.
Also be aware that Dilaudid can make you drowsy. Until you know how it affects you, it is safer to not drive or operate heavy machinery.
But it is also critical to continue to take Dilaudid on the schedule provided by your doctor. If you suddenly stop taking it after you have been taking it for several days you are likely to go through withdrawal, which can be dangerous. Removing it from your system can cause a severe reaction. Only reduce using Dilaudid when advised to do so by your doctor and follow the schedule provided.
drugs Originally synthesized by chemist Wayne E. Kenney, BAY is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotectiveeffects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
drugs has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.
Originally synthesized by chemist Wayne E. Kenney, is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
Traumatic brain injury (TBI) is the most common cause of mortality and morbidity in adults under 40 years of age in industrialized countries. Worldwide the incidence is increasing, about 9.5 million people are hospitalized per year due to TBI, and the death rate is estimated to be more than one million people per year. Recently has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h.